All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

lysergide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
ergot alkaloid derivatives	1621	50-37-3

Description:

Molecule

Description

Molfile Inchi Smiles Synonyms: lysergide D-Lysergic acid diethylamide delysid dextrolysergic acid diethylamide LSD lysergic acid diethylamide d-LSD

Semisynthetic derivative of ergot (Claviceps purpurea). It has complex effects on serotonergic systems including antagonism at some peripheral serotonin receptors, both agonist and antagonist actions at central nervous system serotonin receptors, and possibly effects on serotonin turnover. It is a potent hallucinogen, but the mechanisms of that effect are not well understood. Molecular weight: 323.44 Formula: C20H25N3O CLOGP: 2.69 LIPINSKI: 0 HAC: 4 HDO: 1 TPSA: 39.34 ALOGS: -3.08 ROTB: 3

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.03 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	71 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70	49
kinase-selectivity-class	ACVR2B,AXL,BRAF,EIF2AK3,MAP2K6,STK33	6
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1957	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	222.03	85.50	75	555	104696	42516009
Alcohol abuse	114.37	85.50	23	607	4026	42616679
Drug dependence	111.52	85.50	33	597	29061	42591644
Substance abuse	101.53	85.50	24	606	8881	42611824
Intentional product misuse	94.40	85.50	35	595	61865	42558840

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug abuse	284.41	89.54	86	689	177325	110411199
Drug dependence	180.06	89.54	46	729	49974	110538550
Substance abuse	139.99	89.54	29	746	12434	110576090
Alcohol abuse	133.46	89.54	24	751	4905	110583619
Intentional product misuse	131.71	89.54	45	730	132859	110455665

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
MeSH PA	D006213	Hallucinogens
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D012702	Serotonin Antagonists
MeSH PA	D017366	Serotonin Receptor Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D018490	Serotonin Agents
CHEBI has role	CHEBI:35469	antidepressant
CHEBI has role	CHEBI:35474	anxiolytic drug
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35499	hallucinogen
CHEBI has role	CHEBI:35941	serotonergic agonist
CHEBI has role	CHEBI:51065	dopamine agonist

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	12.56	acidic
pKa2	6.52	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Beta-1 adrenergic receptor	GPCR	P08588	ADRB1_HUMAN		Ki	6.85		CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	6.13		CHEMBL
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN		EC50	6.98		WOMBAT-PK
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	8.86		WOMBAT-PK
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	9.12		WOMBAT-PK
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	7.52		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	8.30		WOMBAT-PK
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	8.40		WOMBAT-PK
5-hydroxytryptamine receptor 7	GPCR	P34969	5HT7R_HUMAN		Kd	8.52		CHEMBL
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN		Ki	6.90		WOMBAT-PK
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	6.47		CHEMBL
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN		Ki	5.81		CHEMBL
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	8.41		CHEMBL
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN		Ki	7.25		CHEMBL
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	8.05		CHEMBL
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		Ki	7.03		CHEMBL
5-hydroxytryptamine receptor 1A	GPCR		5HT1A_RAT		Ki	8.30		CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		Ki	8.46		CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	8.70		CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		Ki	8.42		CHEMBL
D(1A) dopamine receptor	GPCR		DRD1_MOUSE		Ki	6.74		CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	AGONIST	Ki	8.70		IUPHAR
Serotonin 2 (5-HT2) receptor	GPCR		5HT2C_RAT 5HT2A_RAT 5HT2B_RAT		Ki	8.60		CHEMBL

External reference:

ID	Source
C0024334	UMLSCUI
CHEBI:6605	CHEBI
7LD	PDB_CHEM_ID
CHEMBL263881	ChEMBL_ID
DB04829	DRUGBANK_ID
5761	PUBCHEM_CID
17	IUPHAR_LIGAND_ID
729	INN_ID
8NA5SWF92O	UNII
001637	NDDF
15698006	SNOMEDCT_US
D008238	MESH_DESCRIPTOR_UI
8NA5SWF92O	INXIGHT DRUGS

Pharmaceutical products:

None